Clara Blanchard1, Denis Pouchain2, Paul Vanderkam3, Marie-Christine Perault-Pochat4, Rémy Boussageon3, Hélène Vaillant-Roussel5. 1. Department of General Medicine, University of Poitiers, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers Cedex 9, France. cla.blanchard@gmail.com. 2. Department of General Medicine, University of Tours, 10 boulevard Tonnelé, 37032, Tours Cedex 1, France. 3. Department of General Medicine, University of Poitiers, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers Cedex 9, France. 4. Clinical Pharmacology and Awareness Department, University Hospital of Poitiers, 2 rue de la Milétrie, BP 577, 86021, Poitiers Cedex, France. 5. Department of General Medicine and UPU ACCePPT, University of Auvergne, 28 place Henri Dunant, BP 38, 63001, Clermont-Ferrand Cedex 1, France.
Abstract
AIM: Phloroglucinol is a musculotropic anti-spasmodic drug. It is frequently prescribed in many European countries with a considerable cost for health services. The purpose of this study was to review the existing randomised controlled trials (RCT) comparing the efficacy of phloroglucinol treating abdominal pain versus placebo. METHODS: A literature search was carried out up to May 2017 to select RCT comparing the effect of phloroglucinol versus placebo with intensity of abdominal pain as an endpoint. Studies concerning obstetric or gynaecologic-related pain were not included. RESULTS: Three RCT were included and then analysed for risk of bias and meta-analysed. Only one RCT found that phloroglucinol was superior to placebo, although with a high risk of bias. The meta-analysis found a risk ratio of 1.10 (95% CI 0.95, 1.27) with no statistical significance. DISCUSSION: There is insufficient data to justify the wide-spread prescription of phloroglucinol for alleviating abdominal pain.
AIM: Phloroglucinol is a musculotropic anti-spasmodic drug. It is frequently prescribed in many European countries with a considerable cost for health services. The purpose of this study was to review the existing randomised controlled trials (RCT) comparing the efficacy of phloroglucinol treating abdominal pain versus placebo. METHODS: A literature search was carried out up to May 2017 to select RCT comparing the effect of phloroglucinol versus placebo with intensity of abdominal pain as an endpoint. Studies concerning obstetric or gynaecologic-related pain were not included. RESULTS: Three RCT were included and then analysed for risk of bias and meta-analysed. Only one RCT found that phloroglucinol was superior to placebo, although with a high risk of bias. The meta-analysis found a risk ratio of 1.10 (95% CI 0.95, 1.27) with no statistical significance. DISCUSSION: There is insufficient data to justify the wide-spread prescription of phloroglucinol for alleviating abdominal pain.
Authors: S M Patel; W B Stason; A Legedza; S M Ock; T J Kaptchuk; L Conboy; K Canenguez; J K Park; E Kelly; E Jacobson; C E Kerr; A J Lembo Journal: Neurogastroenterol Motil Date: 2005-06 Impact factor: 3.598